Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2009 Aug;66(2):235-44.
doi: 10.1002/ana.21743.

Phase II trial of CoQ10 for ALS finds insufficient evidence to justify phase III

Petra Kaufmann  1 , John L P Thompson, Gilberto Levy, Richard Buchsbaum, Jeremy Shefner, Lisa S Krivickas, Jonathan Katz, Yvonne Rollins, Richard J Barohn, Carlayne E Jackson, Ezgi Tiryaki, Catherine Lomen-Hoerth, Carmel Armon, Rup Tandan, Stacy A Rudnicki, Kourosh Rezania, Robert Sufit, Alan Pestronk, Steven P Novella, Terry Heiman-Patterson, Edward J Kasarskis, Erik P Pioro, Jacqueline Montes, Rachel Arbing, Darleen Vecchio, Alexandra Barsdorf, Hiroshi Mitsumoto, Bruce Levin; QALS Study Group
Collaborators, Affiliations
Clinical Trial

Phase II trial of CoQ10 for ALS finds insufficient evidence to justify phase III

Petra Kaufmann et al. Ann Neurol. 2009 Aug.

Abstract

Objective: Amyotrophic lateral sclerosis (ALS) is a devastating, and currently incurable, neuromuscular disease in which oxidative stress and mitochondrial impairment are contributing to neuronal loss. Coenzyme Q10 (CoQ10), an antioxidant and mitochondrial cofactor, has shown promise in ALS transgenic mice, and in clinical trials for neurodegenerative diseases other than ALS. Our aims were to choose between two high doses of CoQ10 for ALS, and to determine if it merits testing in a Phase III clinical trial.

Methods: We designed and implemented a multicenter trial with an adaptive, two-stage, bias-adjusted, randomized, placebo-controlled, double-blind, Phase II design (n = 185). The primary outcome in both stages was a decline in the ALS Functional Rating Scale-revised (ALSFRSr) score over 9 months. Stage 1 (dose selection, 35 participants per group) compared CoQ10 doses of 1,800 and 2,700 mg/day. Stage 2 (futility test, 75 patients per group) compared the dose selected in Stage 1 against placebo.

Results: Stage 1 selected the 2,700 mg dose. In Stage 2, the pre-specified primary null hypothesis that this dose is superior to placebo was not rejected. It was rejected, however, in an accompanying prespecified sensitivity test, and further supplementary analyses. Prespecified secondary analyses showed no significant differences between CoQ10 at 2,700 mg/day and placebo. There were no safety concerns.

Interpretation: CoQ10 at 2,700 mg daily for 9 months shows insufficient promise to warrant Phase III testing. Given this outcome, the adaptive Phase II design incorporating a dose selection and a futility test avoided the need for a much larger conventional Phase III trial.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest Statement: PK, JLPT, GL, RB, BL have no conflict of interest. HM received honoraria for Advisory Board participation from Avanir, Eisai, Knopp, Neuralstem and Otsuka, and also received grants for clinical trials from Avanir and Knopp. EPP received honoraria for Advisory Board participation from Avanir.

Figures

Figure 1
Figure 1
Participant Flow Diagram
Figure 2
Figure 2
Graphs with box plots of change in plasma CoQ10 concentrations at months 1,5, and 9 by treatment group for Stages 1 and 2 combined
Figure 3
Figure 3
Stage 2: Distribution of ALSFRSr score declines over 9 months, by treatment group
Figure 4
Figure 4
Stage 2: p-values for futility analysis when deceased patients are scored from 0 to 16 in the 9-month ALSFRSr
See this image and copyright information in PMC

References

    1. Annegers JF, Appel S, Lee JR, Perkins P. Incidence and prevalence of amyotrophic lateral sclerosis in Harris County, Texas, 1985-1988. Arch Neurol. 1991;48:589–593. - PubMed
    1. Traynor BJ, Codd MB, Corr B, et al. Incidence and prevalence of ALS in Ireland, 1995-1997: a population-based study. Neurology. 1999;52:504–509. - PubMed
    1. Sorenson EJ, Stalker AP, Kurland LT, Windebank AJ. Amyotrophic lateral sclerosis in Olmsted County, Minnesota, 1925 to 1998. Neurology. 2002;59:280–282. - PubMed
    1. Norris F, Shepherd R, Denys E, et al. Onset, natural history and outcome in idiopathic adult motor neuron disease. J Neurol Sci. 1993;118:48–55. - PubMed
    1. Traynor BJ, Alexander M, Corr B, et al. An outcome study of riluzole in amyotrophic lateral sclerosis--a population-based study in Ireland, 1996-2000. J Neurol. 2003;250:473–479. - PubMed

Publication types

MeSH terms